Equatorial Guinea vs Uganda: Average cost of drugs for extensively drug-resistant tuberculosis
Equatorial Guinea
1,500 constant 2022 US$
in 2024
Uganda
1,709 constant 2022 US$
in 2024
Equatorial Guinea rank
33rd
Uganda rank
30th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Equatorial Guinea
- Uganda
How they compare
Uganda currently reports 1,709 constant 2022 US$ against 1,500 constant 2022 US$ in Equatorial Guinea, a difference of 209 constant 2022 US$.
That makes Uganda's figure about 1.1 times Equatorial Guinea's.
The two have swapped places 2 times across 6 shared years of data; in 2019 it was Uganda ahead.
Equatorial Guinea ranks 33rd and Uganda ranks 30th of 56 countries.
Uganda has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Equatorial Guinea | Uganda | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,000 constant 2022 US$ | 4,963 constant 2022 US$ | 963 constant 2022 US$ | Uganda |
| 2020s | 2,301 constant 2022 US$ | 3,247 constant 2022 US$ | 946 constant 2022 US$ | Uganda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Equatorial Guinea or Uganda?
- Uganda, at 1,709 constant 2022 US$ against 1,500 constant 2022 US$ in Equatorial Guinea as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Equatorial Guinea and Uganda?
- 209 constant 2022 US$, with Uganda ahead.
- How many years of comparable data are there for Equatorial Guinea and Uganda?
- 6 years are reported by both, from 2019 to 2024.
- How do Equatorial Guinea and Uganda rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Equatorial Guinea ranks 33rd and Uganda ranks 30th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.